The Supreme Court recently made a significant ruling regarding the FDA's regulatory approval process for the abortion drug mifepristone. This decision comes in the wake of the landmark ruling in 2022 that overturned Roe v. Wade, a pivotal case in abortion rights.
In a unanimous decision, the high court determined that the challengers to the FDA lacked standing to sue the government. Justice Brett Kavanaugh, who authored the opinion, emphasized that a plaintiff's objections to a drug's availability do not automatically grant them the right to sue under Article III of the Constitution.
